EUVIMEDEUVIMED entdecken
Crossref

Cross‐sectional study using the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Tract Instrument 2.0 ( UCLA SCTC GIT 2.0) for gastrointestinal disorders of systemic sclerosis

Satoko Hisada, Saki Takeuchi, Takahisa Tozawa, Yoshihiro Yamada, Yumi Ito iD, Masanari Kodera

The Journal of Dermatology · 2024

DOI: 10.1111/1346-8138.17327 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Satoko Hisada und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Japan Community Health Care Organization Chukyo Hospital, Nagoya, Japan. Hauptthemen laut MEDLINE: Gastrointestinal Diseases, Severity of Illness Index. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to identify severe gastrointestinal ailments in patients with systemic sclerosis (SSc), investigate the role of antibodies in gastrointestinal disorders, and explore the relationship between limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) in terms of gastrointestinal involvement and its association with skin stiffness. We used the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Tract Instrument 2.0 (UCLA SCTC GIT 2.0) questionnaire to assess gastrointestinal disturbances in 100 patients with SSc. Gastrointestinal impairment was categorized into three levels: absence of or minor symptoms, moderate symptoms, and severe symptoms, as indicated by the total gastrointestinal tract (GIT) score. Comparing 27 patients with dcSSc and 73 patients with lcSSc, severe gastrointestinal disturbances were found in 7.4% of patients with dcSSc and 4.1% of patients with lcSSc. A total of 18.0% of anticentromere antibody (ACA)–positive patients exhibited moderate to severe symptoms, while 9.1% of antitopoisomerase 1 antibody–positive patients displayed similar symptoms. The average disease duration in patients with severe symptoms was 15.0 years, in those with moderate symptoms was 10.3 years, and in those who were symptom‐free or mildly affected was 8.5 years. Among 16 patients with moderate to severe gastrointestinal disorders, a positive correlation was observed between the modified Rodnan skin thickness score (mRSS) and total GIT score. In addition, a positive correlation was identified between fecal incontinence and mRSS, with weaker correlations for reflux and bloating symptoms. Patients with gastrointestinal disorders showed a tendency to worsen over time, particularly in ACA‐positive patients with dcSSc. Furthermore, a correlation was observed between mRSS and fecal incontinence, reflux, and abdominal bloating in patients with moderate to severe gastrointestinal disturbances.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal DiseasesSeverity of Illness IndexHumansMaleFemaleMiddle AgedCross-Sectional StudiesAdultSurveys and QuestionnairesAgedScleroderma, SystemicScleroderma, DiffuseAutoantibodiesScleroderma, LimitedGastrointestinal TractDNA Topoisomerases, Type IAntibodies, Antinuclear

Stichwörter der Autor:innen

UCLA SCTC GIT 2.0gastrointestinal disordersmodified Rodnan total skin scoresystemic sclerosis

Substanzen

anticentromere antibodyAutoantibodiesDNA Topoisomerases, Type IAntibodies, Antinuclear

Autor:innen und Institutionen

  • Division of Dermatology, Japan Community Health Care Organization Chukyo Hospital, Nagoya, Japan.

ORCID-Profile: Yumi Ito

Zitieren

APA

Hisada, S., Takeuchi, S., Tozawa, T., Yamada, Y., Ito, Y., & Kodera, M. (2024). Cross‐sectional study using the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Tract Instrument 2.0 ( UCLA SCTC GIT 2.0) for gastrointestinal disorders of systemic sclerosis. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17327

Vancouver

Hisada S, Takeuchi S, Tozawa T, Yamada Y, Ito Y, Kodera M. Cross‐sectional study using the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Tract Instrument 2.0 ( UCLA SCTC GIT 2.0) for gastrointestinal disorders of systemic sclerosis. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17327

BibTeX
@article{Hisada2024,
  author = {Hisada, Satoko and Takeuchi, Saki and Tozawa, Takahisa and Yamada, Yoshihiro and Ito, Yumi and Kodera, Masanari},
  title = {Cross‐sectional study using the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Tract Instrument 2.0 ( UCLA SCTC GIT 2.0) for gastrointestinal disorders of systemic sclerosis},
  journal = {The Journal of Dermatology},
  year = {2024},
  doi = {10.1111/1346-8138.17327}
}
Kostenlos starten →